Quetiapine and Hyper Sexuality
No Thumbnail Available
Date
2025-03-31
0000-0001-5835-7334 Journal Title
Journal ISSN
Volume Title
Publisher
Brieflands
Abstract
Context: Sexual dysfunction is identified as a routine side effect following antipsychotic consumption; however, different medications present significant differences. Objectives: This study aimed to report a schizoaffective bipolar-type case of hypersexuality following quetiapine therapy and to systematically review the available instances of the association between hypersexuality and quetiapine. Methods: Cases of hypersexuality after taking quetiapine were searched without time restriction until November 16, 2022, under the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guideline. The terms "Compulsive sexual behavior", "Hypersexuality", "Sexual addiction", "Libido", "Compulsive sexual disorder", "Sexual compulsivity", "Hypersexual", and "Quetiapine" were searched in PubMed, Scopus, and ISI Web of Knowledge databases. All case reports and case series were included. Extracted data include authors, year, age, sex, underlying diseases, medication types, medication dose, the effect of medication, and treatment trends. Results: Alongside the present case in this study, six studies, including seven cases, reported the relationship between hypersexuality and quetiapine. Four hypersexual cases improved by adding quetiapine to their treatment panel. On the other hand, similar to the present case in this study, three cases indicated hypersexuality after quetiapine consumption; one of them was treated after 4 - 6 weeks without dosage change, and others achieved improvement following dosage reduction. Conclusions: Although some evidence reported improvement in hypersexuality following quetiapine consumption, an increased sexual drive has also been observed after taking quetiapine. These findings may present the dual role of quetiapine in sexual functioning, suggesting more attention to underlying disease, dosage, and medication interactions.